A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors and Lymphomas.

Trial Profile

A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors and Lymphomas.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2011

At a glance

  • Drugs NTB 011 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2011 Planned End Date changed from 1 May 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Mar 2011 Additional lead trial centre identified as reported by Barbara Ann Karmanos Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top